Siemens’ PETNET Solutions Signs Exclusive Agreement
Siemens’ PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA Inc., has entered into a nationwide agreement with U.K.-based Blue Earth Diagnostics Ltd. for the exclusive commercial manufacturing and distribution of Fluciclovine (18F), an investigational positron emission tomography and computed tomography (PET/CT) radiopharmaceutical. Fluciclovine (18F) is being studied for prostate imaging in clinical trials conducted in the U.S., Japan, Italy, Norway, Sweden and Finland. The F-18-based radiopharmaceutical has a long half-life, which may facilitate its geographical distribution to clinical trial sites and then to clinical imaging centers once it gains approval from the Food and Drug Administration (FDA).
Prostate cancer is the second-leading cause of cancer in men worldwide, with 220,800 men expected to be diagnosed in 2015 in the U.S., according to the American Cancer Society. Currently, approved diagnostic options for prostate cancer include PET/CT scans using an injectable radiopharmaceutical to evaluate the extent of metastatic disease specifically for soft tissues and/or bony anatomy.
With its large commercial radiopharmacy network in the U.S., Siemens’ PETNET Solutions provides wide access to PET radiopharmaceuticals for oncology, cardiology and neurology to imaging physicians and patients. Blue Earth Diagnostics Ltd. is a private U.K.-based diagnostic company backed by Syncona Partners LLP, a subsidiary of the Wellcome Trust that is developing and commercializing PET agents for cancer.
“Siemens’ PETNET Solutions is pleased to announce its U.S.-wide agreement with Blue Earth Diagnostics Ltd. to distribute its Fluciclovine (18F) PET radiopharmaceutical in the United States once it gains FDA approval,” says Barry Scott, CEO of Siemens’ PETNET Solutions. •